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Pretreatment of Endothelial Progenitor Cells With Osteopontin
Enhances Cell Therapy for Peripheral Vascular Disease
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*Regenerative Medicine Institute (REMEDI), National Centre for Biomedical Engineering Science (NCBES),
National University Ireland Galway (NUIG), Galway, Ireland
†Department of Anatomy, National University Ireland Galway (NUIG), Galway, Ireland
‡Medtronic, Galway, Ireland
§Department of Respiratory Medicine, University College Hospital Galway, Galway, Ireland
Tissue necrosis resulting from critical limb ischemia (CLI) leads to amputation in a significant number of
patients. Autologous cell therapy using angiogenic cells such as endothelial progenitor cells (EPCs) holds
promise as a treatment for CLI but a limitation of this treatment is that the underlying disease etiology that
resulted in CLI may also contribute to dysfunction of the therapeutic EPCs. This study aimed to elucidate
the mechanism of EPC dysfunction using diabetes mellitus as a model and to determine whether correction
of this defect in dysfunctional EPCs ex vivo would improve the outcome after cell transplantation in the
murine hind limb ischemia model. EPC dysfunction was confirmed in a homogenous population of patients
with type 1 diabetes mellitus and a microarray study was preformed to identify dysregulated genes. Notably,
the secreted proangiogenic protein osteopontin (OPN) was significantly downregulated in diabetic EPCs.
Furthermore, OPN-deficient mice showed impaired recovery following hind limb ischemia, suggesting a
critical role for OPN in postnatal neovascularization. EPCs isolated from OPN KO mice showed decreased
ability to adhere to endothelial cells as well as impaired angiogenic potential. However, this dysfunction
was reversed upon exposure to recombinant OPN, suggesting that OPN may act in an autocrine manner on
EPCs. Indeed, exposure of OPN knockout (KO) EPCs to OPN was sufficient to induce the secretion of
angiogenic proteins (IL-6, TGF-α, and FGF-α). We also demonstrated that vascular regeneration following
hind limb ischemia in OPN KO mice was significantly improved upon injection of EPCs preexposed to
OPN. We concluded that OPN acts in an autocrine manner on EPCs to induce the secretion of angiogenic
proteins, thereby playing a critical role in EPC-mediated neovascularization. Modification of cells by expo-
sure to OPN may improve the efficacy of autologous EPC transplantation via the enhanced secretion of
angiogenic proteins.
Key words: Endothelial progenitor cell (EPC); Stem cell; Diabetes mellitus; Osteopontin; Vascular disease;
Ischemia
INTRODUCTION survival rate of less than 30%. Thus, the need to develop
new therapies is imperative to improving both the qual-
ity of life and survival rate of patients. Currently, boneCritical limb ischemia (CLI) is the end stage of
peripheral vascular disease (PAD) and leads to ischemia, marrow-derived stem and progenitor cells show some
promise as a therapeutic for CLI [reviewed in (21)].resulting in pain at rest and tissue loss. Improvement
of blood flow often requires surgical or endovascular Endothelial progenitor cells (EPCs) show particular
promise as a therapeutic agent as numerous studies sup-revascularization. However, in over one third of patients
revascularization either fails or is not possible due to port their role in augmenting angiogenesis (14). How-
ever, a potential limitation of autologous EPC therapy iscomorbid complications (1). In these patients major
amputation is often necessary and results in a 5-year that the disease state that results in CLI may also
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adversely affect EPC function and thus limit therapeutic angiogenesis assays (23,31). Similarly, bone marrow-
derived mononuclear cells derived from streptozotocin-efficacy. Indeed, in diabetes mellitus, where CLI is a
common complication, patients have fewer EPCs than induced diabetic mice yield fewer EPCs and they exhibit
dysfunction, as they are less likely to incorporate intohealthy volunteers (9,23,31), while patients with type 2
diabetes complicated by peripheral vascular disease newly forming vascular structures in a Matrigel plug
assay than those from healthy mice (29). Beyond effectshave an even further reduction in the number of EPCs
and in these patients EPC number inversely correlates mediated directly by the cells, it has also been noted
that conditioned media from T1DM EPCs has a reducedwith glycemic control (9).
If a simple reduction in EPC number is the primary capacity to mediate angiogenesis and may actually inhibit
angiogenesis in vitro (23). Taken together, these data sug-issue then autologous cell therapy, where an infusion of
cells is delivered directly to the diseased area, should be gest that the use of autologous cells may be limited by
the inherent dysfunction of the transplanted cells. There-sufficient to restore normal function. However, the issue
is more complex as studies have revealed that EPCs fore, we used EPCs from type 1 diabetic patients as a
model for EPC dysfunction with the goal of elucidatingfrom diabetic patients and animals are not only decreased
in number but are also dysfunctional. EPCs from techniques to manipulate the EPCs to increase their thera-
peutic potential in a model of cell transplantation.patients with type 2 diabetes mellitus (T2DM) exhibit
decreased adhesion to activated endothelial cells and to We used microarray analysis to identify genes that
are dysregulated in diabetic EPCs and determine if thesematrix molecules including collagen and fibronectin,
and EPCs derived from patients with both T1DM and genes contribute to EPC-mediated angiogenesis. The
expression of osteopontin (OPN) was found to beT2DM are impaired in their ability to form tubules in
Figure 1. Human endothelial progenitor cell (EPC) characterization. EPCs were characterized by their ability to uptake acetylated
low-density lipoprotein (LDL) and Ulex europaeus agglutinin-1 (UEA-1) lectin. (A) Brightfield picture of EPCs. (B) Uptake of
acetylated LDL and (C) UEA-1 lectin were observed. (D) Colocalization shows that greater than 90% of the cells were dual stained
for both acLDL and UEA-1 lectin. Scale bar: 100 µm.
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Figure 2. EPCs from patients with type 1 diabetes mellitus (T1DM) are reduced in number and dysfunctional. (A) EPCs were
isolated from the peripheral blood of patients with T1DM, cultured, and counted 4 days after plating on fibronectin-coated dishes.
Patients with T1DM had fewer EPCs than nondiabetic controls (n = 4), *p < 0.05. (B) Adhesion to tumor necrosis factor-α (TNF-
α) activated but not nonactivated endothelial cells was impaired in diabetes mellitus (n = 3), ***p < 0.001. (C) Representative
images from a Matrigel tubule assay showing EPCs from patients with T1DM had a reduced ability to support tubule formation.
Scale bar: 20 µm. (D) Quantification of images shown in (C). T1DM cells have a reduced ability to induce angiogenesis in vitro
(n = 4), ***p < 0.001. HUVEC, human umbilical cord vein endothelial cell.
decreased in diabetic EPCs. OPN is a secreted glycopro- ischemia is impaired in OPN knockout (KO) mice and
we went on to demonstrate that EPCs from OPN knock-tein that is involved in cell migration, cell survival,
regulation of immune cell function, inhibition of calcifi- out mice are dysfunctional. We found that OPN may act
on EPCs in an autocrine manner, resulting in the secre-cation, and control of tumor cell phenotype (5,10,11,32).
Interestingly, OPN has been implicated in the process of tion of additional angiogenic factors. Furthermore, in a
murine model of hind limb ischemia in the OPN knock-neovascularization in various cancer models and periph-
eral ischemia (10,11). OPN overexpression is associated out mouse, a model of EPC dysfunction, injection of
OPN KO EPCs preincubated with OPN resulted inwith the increased invasiveness of cancers while inhibi-
tion of OPN suppresses tumorigenicity (12,25,27,30,35). improved blood flow to the injured limb. These data
indicate that OPN is a potential target for the regulationStudies in noncancerous animal models also support a
role for OPN in neovascularization (7,8). of the EPC-mediated angiogenic response to ischemic
vascular injury and suggest a novel method to enhanceDespite these studies, the precise role of OPN in ves-
sel formation is poorly understood. Further, the relation- therapeutic efficacy of autologous EPC transplantation
in peripheral vascular disease.ship between OPN and EPC function is currently
unknown. Therefore, we sought to elucidate the underly-
MATERIALS AND METHODSing cause of EPC dysfunction in patients with type 1
Subject Recruitmentdiabetes mellitus, a model for EPC dysfunction, and
assess the putative role of OPN in ischemia and neovas- Patients with poorly controlled type 1 diabetes (as
defined by HbA1/c > 10%) who were on insulin for morecularization. We found that recovery from hind limb
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Figure 3. Decreased osteopontin (OPN) expression is observed in diabetic EPCs. (A) A heat map showing the gene expression
pattern of genes with a greater than twofold difference in EPCs from healthy controls (n = 4) and EPCs from type 1 diabetes
mellitus (T1DM). Three hundred and sixty genes were upregulated in T1DM and 15 were downregulated. OPN was identified as
having a 9.6-fold decrease in T1DM EPCs. (B) To test if OPN will restore function to diabetic EPCs, EPCs from both healthy and
diabetic subjects were exposed to recombinant OPN. Exposure to OPN was able to significantly restore tubule formation mediated
by EPCs in both human and in New Zealand white rabbits (C) (n = 3). *p < 0.05; **p < 0.01; ***p < 0.001.
than 1 year and not on any other medications were peripheral blood mononuclear cells (PBMNCs) were
isolated by Ficollpaque (GE Healthcare) density centrif-recruited from the Diabetes Day Centre, University Col-
lege Hospital Galway, Ireland. Patients with micro- or ugation. After purification with three washing steps, 10 ×
106 or 2 × 106 cells (for cell quantification) were platedmacrovascular complications were excluded from the
study. Microvascular complications were defined as the on fibronectin-coated six-well plates or four-well glass
slides, respectively. Cells were incubated for 4 days atpresence of microalbuminuria, diabetic retinopathy, and
neuropathy. Macrovascular complications were defined which point the supernatant was discarded, cells were
washed with PBS, and fresh endothelial basal mediaas the presence of any previous history of acute coronary
syndrome, peripheral vascular disease, and cerebrovas- (EBM2) was added and changed daily until day 7, when
EPCs were used.cular disease. All subjects gave informed consent and
were recruited with ethical approval from University
College Hospital Galway Clinical Research Ethics Com- Adhesion to Endothelial Cells
mittee and the investigation conforms to the principles Adhesion to endothelial cells was determined accord-
outlined in the Declaration of Helsinki. ing to previously described techniques (16). In brief, a
Isolation of EPCs monolayer of human umbilical vein endothelial cells
(HUVECs; Lonza) was prepared 48 h before the assayEPCs were isolated according to previously described
techniques with some modifications (16). Briefly, by plating 2 × 105 cells (passage 5 to 10) in each well
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Table 1. Top 10 Genes Underexpressed in Type 1 Diabetes the marginal artery under anesthesia. This study was
Mellitus Endothelial Progenitor Cells (EPCs) Compared approved by the National University Ireland, Galway
to Healthy Control EPCs (NUIG) Animal Care and Use Committee.
Fold Total RNA Extraction
Gene Name Change p-Value GenBank
Total RNA was isolated from day 4 EPCs using RNA
Mini Kit (Qiagen) as described by the manufacturer. TheSPP1/OPN −9.6 0.0229 M83248
CD109 −4.4 0.0192 AL110152 concentration of isolated total RNA was analyzed using
KIAA0555 −3.1 0.0052 AI962693 NanoDrop counter. QuantIt DNA, High Sensitivity kit
NDN −3.1 0.0139 U35139 (Invitrogen) was used to detect the presence of any
CLDN23 −2.4 0.0112 BF110053 genomic DNA in the total RNA samples.
CLDN23 −2.4 0.0113 BF110053
B4GALT1 −2.4 0.0177 AV687517 Microarray Analysis
COL23A1 −2.2 0.0181 AI690433 The GeneChip, HG-U133 Plus 2.0 (Homo sapiens) inKIAA1706 −2.2 0.0046 AB051493
situ oligonucleotide array (Affymetrix. Inc., Santa Clara,LTBP2 −2.1 0.0013 NM_000428
CA) was used. The GeneChip covers the transcribed
SPP1/OPN, secreted phosphoprotein 1/osteopontin; CD109, cluster of human genome, comprised of 54,675 probe sets and
differentiation 109; KIAA0555, Janus kinase and microtubule-interact- ESTs. The CEL file, which stores the results of theing protein 2; NDN, necdin; CLDN23, claudin 23; B4GALT1, β-1,4-
intensity calculations on the pixel values of probes, wasgalactosyltransferase 1; COL23A1, collagen, type XXIII, α1;
KIAA1706, endonuclease/exonuclease/phosphatase family domain preprocessed as the first-order data analysis using Micro-
containing 1; LTBP2, latent transforming growth factor-β binding pro-
array Suite (MAS) algorithm, Affymetrix GeneChiptein 2.
Operating Software (GCOS). The data sets were normal-
ized by per-chip, per-gene normalization method using
GeneSpring bioinformatics software (GeneSpring GX
7.3.1, Silicon Genetics, Redwood City, CA). Gene filter-of a four-well glass slide. Twelve hours before the assay
ing on normalized intensity followed by one-waythe HUVECs in some experiments were treated with
ANOVA, multiple testing correction, Benjamini andtumor necrosis factor-α (TNF-α; BD Biosciences) 1 ng/
Hochberg false discovery rate, and Tukey’s post hocml or media. After the 12 h, 1 × 105 EPCs labeled with
testing based on values of p < 0.05 and fold changes1,1′- dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine
>2.0-fold was performed to generate list of gene expres-iodide (DiI) were added to the HUVECs and incubated
sion profile.for 3 h. Nonattached cells were then gently removed
with PBS and adherent cells were fixed with 4% para-
Primer Sequencesformaldehyde (PFA) and counted by a blinded observer.
Primers for OPN (CAGAGCACAGCATCGTCGG;
GGCAAAAGCAAATCACTGCAA) and the house-Matrigel Tubule Assay
The assay was performed according to previously
described techniques (16). Matrigel (BD Biosciences) Table 2. Top Genes Overexpressed in Type 1 Diabetes
Mellitus EPCs Compared to Healthy Control EPCswas thawed on ice and placed in four-well glass slides
and incubated at room temperature for 30 min to allow
Foldfor solidification. EPCs were incubated at 37°C for 24
Gene Name Change p-Value GenBankh with or without 5 µg/ml OPN (Sigma) and labeled
with DiI. Labeled EPCs (2 × 104) were coplated with GBP3 11.2 0.0001 AL136680
4 × 104 HUVECs and tubule formation was determined Unidentified 7.6 0.0239 M87789
at 12 h for human EPCs and 24 h for murine EPCs and Unidentified 5.6 0.0307 M87790
Unidentified 5.5 0.0024 AF116710conditioned media. Tubule formation was defined as a
C6orf32 4.9 0.0056 AB002384structure exhibiting a length four times its width. The num-
IGLJ3 4.5 0.0298 X57812ber of tubules formed was assessed by a blinded observer.
Unidentified 4.4 0.0018 AW193600
LEF1 4.2 0.0079 AF288571Alloxan-Induced Diabetic Rabbit Model Unidentified 4.1 0.0046 AW292872
Unidentified 4.1 0.0210 AA680302Diabetes was induced in male New Zealand White
rabbits using intravenous injection of alloxan (150 mg/
GBP3, guanylate binding protein 3; C6orf32, chromosome 6 openkg). Rabbits with plasma glucose of >22 mmol/L were reading frame 32; IGLJ3, immunoglobulin lambda joining 3; LEF1,
lymphoid enhancer-binding factor 1.included for this study. Phlebotomy was performed via
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Figure 4. Absence of osteopontin (OPN) impairs neovascularization. Hind limb ischemia was induced in wild-type (WT) and
OPN knockout (KO) mice. Laser Doppler blood flow (LDBF) analysis was performed at days 7, 14, and 28 and animals were
sacrificed on day 28. (A) Representative Doppler images before and after induction of ischemia. Images at day 28 show an
improvement in blood flow in WT animals but not in OPN KO mice. (B) Quantitative analysis of the laser Doppler images
displayed a significant decrease in recovery in OPN-deficient mice. Results are shown as the ratio of the ischemic limb to the
control limb. (C) Microvascular density was decreased in the ischemic limb of OPN KO mice when compared to the ischemic
limb of WT mice. No difference was noted in microvascular density in the nonischemic limbs between OPN KO and WT
animals (n = 5). *p < 0.05.
keeping gene, cyclophilin A (TGCTGGACCCAACA to confirm the PCR results. Each sample was analyzed
in triplicate.CAAATG; CATGCCTTCTTTCACTTTGCC) (Sigma
Genosys) were designed using PrimerExpress software.
Isolation and Identification of Murine Endothelial
Progenitor CellsReal-Time PCR
The ABI Prism 7000 Sequence Detection System The hind limbs were separated from the body and the
epiphyses were removed from both ends. The marrow(Applied Biosystems) with One Step QuantiTect SYBR
Green PCR kit (Qiagen) was used for all PCR experi- was flushed from the bone in 5 ml of endothelial growth
medium 2 (EGM-2) and the media with bone marrowments. The reactions were performed according to the
manufacturer’s instructions with minor modifications. A was collected and centrifuged at 1,700 rpm for 25 min.
The supernatant was removed and cells were resus-sample volume of 25 µl was incubated for 30 min at
50°C; 95°C for 15 min; followed by 40 cycles of 15 s pended in 1 ml of red cell lysis buffer (Sigma). Cells
were collected at 1,700 rpm for 5 min and washed twiceat 95°C and 30 s at 60°C. The dissociation curves were
generated using a temperature range between 60°C and in PBS. Cells were resuspended in 4 ml of EBM2 and
plated on a fibronectin-coated plate. EPCs were identified95°C. All reactions were further analyzed by electropho-
resis on 2% agarose gels stained with SyBrGreen dye by direct fluorescent staining to detect fluorescein iso-
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thiocyanate (FITC)-Ulex europaeus agglutinin-1 lectin nal control within each mouse. Animals were anesthe-
tized with ketamine and xylazine and maintained with(Sigma) and DiI-acetylated low density lipoprotein
(acLDL) (Invitrogen) as previously described (13). isoflurane. In the second set of experiments, injection of
1 × 106 EPCs resuspended in 200 µl of EBM2 (with no
supplements added) was performed. There were sixMurine Hind Limb Ischemia Model injections into the thigh muscle at the time of surgery.
C57BL/6 (strain code 027) (wild-type; WT) and
OPN−/OPN−[B6.12956(Cg)-spp1tm1Blh/J] (OPN-KO) Laser Doppler Blood Flow Assessment (LDBF)[B6.12956(Cg)-spp1tm1Blh/J] mice were purchased
Animals were anaesthetized and placed on a heatingfrom Charles River Lab and Jackson Laboratory, respec-
table at 37°C before scanning to minimize temperaturetively. OPN KO and WT mice aged between 8 and 10
variation. The blood flow in the foot pads of both limbsweeks of age were used. The mice were housed at the
was measured using a laser Doppler blood flow analyzeranimal facility in the Regenerative Medicine Institute
(PeriScan PIMII, Perimed Inc.) immediately before and(REMEDI), NCBES, NUIG. All procedures were
after surgery as well as on postoperative days 7, 14, andapproved by the Minister of Health and Children under
28. Microvasulature blood flow was displayed in athe Cruelty to Animals Act, 1876. Unilateral hind limb
color-coded image. Analysis was performed by compar-ischemia was created in WT and OPN KO mice as pre-
ing blood flow in the ischemic limb (left) to the nonis-viously described (19). In brief, the left femoral artery
chemic limb (right) to further minimize variations dueand its associated branches were isolated, ligated, and
to ambient light and temperature.excised. The contralateral hind limb served as an inter-
Figure 5. Murine endothelial progenitor cell (EPC) characterization. EPCs were characterized by their ability to uptake acetylated
LDL and UEA-1 lectin. (A) Nuclei were stained with Hoescht. (B) Uptake of acetylated LDL and (C) UEA-1 lectin was observed.
(D) Colocalization shows that greater than 90% of the cells were dual stained for both acLDL and UEA-1 lectin. Scale bar: 20 µm.
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Figure 6. OPN exerts autocrine effects on EPCs inducing the secretion of angiogenic factors. (A)
To assess the ability of EPCs to adhere to sites of injury, adhesion to TNF-α activated endothelial
cells was measured in murine EPCs. EPCs from OPN knockout (KO) mice did not adhere as well
as wild-type (WT) EPCs. Exposure to OPN increased the ability of KO EPCs to adhere, suggesting
that OPN plays a role in adhesion (n = 3). **p < 0.01; ***p < 0.001. (B) Angiogenesis induced by
murine EPCs was determined with a Matrigel assay. WT EPCs induced the formation of signifi-
cantly more tubules than OPN KO EPCs. Exposure to OPN reversed this dysfunction in OPN KO
EPCs. All tubule counts were normalized to the baseline levels of tubules formed with HUVECs
alone (n = 3). *p < 0.05. (C) Angiogenesis induced by conditioned media from murine EPCs was
measured with a Matrigel tubule assay. Conditioned media from WT EPCs induced tubule forma-
tion, suggesting angiogenesis may be mediated by the secretion of factors from the EPCs. Neutral-
ization of OPN did not dampen tubule formation, indicating other factors may be increasing
angiogenesis (n = 3). *p < 0.05. (D) Protein secretion was measured with an angiogenesis array.
Three proteins that had decreased expression in OPN KO cells were identified and expression of
all three protein expression levels was returned to WT levels upon exposure to OPN, suggesting
OPN may induce the secretion of angiogenic factors (n = = 3). *p < 0.05. FGF, fibroblast growth
factor; IL-6, interleukin-6; TGF-α, transforming growth factor-α.
Collection of Conditioned Media background values were subtracted. All data were nor-
malized to the positive control spots to control for differ-EPCs were grown as described until day 6. On the
ences between arrays.6th day of culture the media was removed and cells were
washed three times in PBS. One milliliter of fresh Statistical AnalysisEBM2 was then added to each well of a six-well plate
Data are presented as mean ± SEM. Statistical analy-and the plates were then incubated for 24 h at which
sis was performed by unpaired Student’s t-test for com-point the media was collected for use in the Matrigel
parisons between two groups and by one-way analysistubule assay. Conditioned media for the angiogenesis
of variance followed by Bonferroni correction for com-array was obtained by incubating day 6 EPCs in growth
parison between more than two groups. A value of p <factor-free EBM2 for 48 h.
0.05 was considered significant.
Angiogenesis Array
RESULTSConditioned media (100 µl) was hybridized to each
EPC Dysfunction in Type 1 Diabetes Mellitusmembrane of an antibody-sandwich angiogenesis array
(Panomics) according to manufacturer’s guidelines. We first sought to determine if EPC number and
function were impaired in a homogenous population ofExpression intensities were determined with Image J and
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patients with T1DM that did not have micro- or macro- OPN in EPC Dysfunction in DM
vascular complications. EPCs were isolated from four
patients with T1DM with a mean HbA1/c of 12.5 ± 4.3% Having identified diabetes as a model for EPC dys-
function, we sought to elucidate the underlying cause ofand a mean duration of diabetes of 7 ± 2.3 years, and
four gender- and age-matched (22.3 ± 4.3 vs. 22.8 ± 2.1 this dysfunction. Therefore, a microarray was performed
on EPCs obtained from diabetic and control subjects andyears old) healthy volunteers were recruited (Fig. 1).
EPCs from patients with T1DM were reduced in both the top 10 genes up- and downregulated are shown (Fig.
3A, Tables 1 and 2). Three hundred and sixty genesnumber and function when compared to EPCs from
healthy volunteers (Fig. 2). were found to be upregulated in T1DM EPCs and 15
Figure 7. Treatment with OPN-exposed EPCs enhances blood flow to ischemic limbs. Hind limb ischemia was induced in OPN
KO mice and intramuscular (IM) injection of EPCs was preformed. (A) Representative Doppler images before and after the
induction of ischemia demonstrate an increase in blood flow in the ischemic limbs of mice treated with OPN preconditioned EPCs.
(B) Quantitative analysis of the laser Doppler blood flow data demonstrates an accelerated angiogenic response to ischemia. At
day 7 mice injected with OPN-preconditioned EPCs showed significantly improved blood flow when compared to mice injected
with diluent alone and this improvement is further enhanced at day 14. Results are shown as the ratio of the ischemic limb to the
control limb (n = at least 5). *p < 0.05, **p < 0.01 compared to control.
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genes downregulated twofold or greater. OPN was need to be physically present to enhance angiogenesis
or if they are secreting factors that act in a paracrinefound to be markedly reduced in diabetic EPCs and this
was confirmed by qRT PCR where OPN was downregu- manner to enhance angiogenesis.
lated 26.89-fold in diabetic EPCs.
To further address the potential importance of OPN EPCs Enhance Angiogenesis in a Paracrine Manner
in EPC-mediated angiogenesis, diabetic and healthy To determine if EPCs function to enhance angiogen-EPCs were incubated with OPN and a Matrigel tubule
esis in a paracrine manner, conditioned media (CM)
assay was performed. Impairment in tubule formation from WT and OPN KO EPCs was obtained and incu-from diabetic EPCs (compared to nondiabetic EPCs) bated with HUVECs in the Matrigel tubule assay. CM
was reversed upon exposure to recombinant OPN. Fur- from WT but not OPN KO EPCs induced a significant
thermore, this finding was also confirmed with EPCs
angiogenic response (Fig. 6C). To determine if OPNfrom an alloxan-induced diabetic rabbit model: tubule
was responsible for this paracrine effect CM was col-formation was restored to nondiabetic levels after expo- lected from WT cells and incubated with an OPN neu-
sure to recombinant OPN protein (Fig. 3C).
tralizing antibody. If OPN induces tubule formation, its
neutralization in the CM should abrogate the angiogenicRole of OPN in Angiogenesis
response. Surprisingly, incubation with the OPN neutral-Having observed that EPCs from patients with T1DM izing antibody did not significantly decrease tubule for-
were dysfunctional and expressing decreased levels of
mation (Fig. 6C), suggesting that OPN does not enhanceOPN, we went on to explore the role of OPN in angio-
angiogenesis directly. Thus, we went on to explore othergenesis and vascular wound healing. Hind limb ischemia possible roles OPN could play in mediating angiogenesis.
was induced in OPN KO mice and laser Doppler blood
flow analysis was performed. Postoperative results in
OPN Acts on EPCs in an Autocrine Mannerthe ischemic limb demonstrate that blood flow was
to Enhance Angiogenesisrestricted to about 15% of the flow in the control limb
in both WT and KO animals. By day 28 blood flow in An alternate mechanism for OPN-mediated angio-
genesis is via an autocrine effect on EPCs to secretethe ischemic footpad of WT mice was restored to levels
found in the control limb; however, blood flow was angiogenic factors. Thus, incubation with exogenous
OPN should be sufficient to elicit the secretion of pro-restored to only about 23% of WT levels in the KO
animals (Fig. 4A, B). In addition to decreased blood teins that enhance the angiogenic response. Indeed, we
found that incubating EPCs with recombinant OPN wasflow, we also found that microvascular density was
decreased in the ischemic limbs of OPN KO mice when sufficient to enhance tubule formation to levels obtained
from WT cells (Fig. 6B). In fact, incubation with recom-compared to the ischemic limb of WT mice (Fig. 4).
binant OPN-induced KO cell adhesion to activated
Role of OPN in EPC Function endothelial cells to levels surpassing WT cells (Fig. 6A).
Furthermore, if KO cells are incubated with OPN for 24We next sought to determine if there was a direct link
between the impaired angiogenesis observed in KO mice h, followed by removal of the OPN-containing media,
and fresh media (without OPN) is added and collectedand EPC function. We first determined the ability of WT
and KO EPCs to adhere to activated endothelial cells. after 24 h this media is still able to enhance angiogen-
esis, supporting the possibility that OPN is inducing theEPCs were obtained from the bone marrow of the mice
and dual staining of DiI-acetylated LDL and FITC-lectin secretion of angiogenic proteins from EPCs (Fig. 6C).
To further address this, a chemiarray was used to deter-were confirmed (Fig. 5). EPCs from OPN KO mice dis-
played impaired adherence when compared to WT EPCs mine if there was differential secretion between WT
EPCs, KO EPCs, and KO EPCs exposed to OPN. The(Fig. 6A). Furthermore, when OPN KO EPCs were com-
pared to WT EPCs in a Matrigel tubule assay we secretion of three angiogenic proteins, fibroblast growth
factor-α (FGF-α), interleukin 6 (IL-6), and transformingobserved that WT EPCs induced significantly more
tubule formation than KO EPCs (Fig. 6B). Taken growth factor-α (TGF-α), were found to be downregu-
lated from KO cells when compared to WT (Fig. 6D).together, these data suggest that OPN KO EPCs are
impaired in their ability to adhere to the site of injury as Interestingly, exposure of KO cells to OPN restored the
secretion of these proteins to WT levels. Taken together,well as their ability to induce angiogenesis. Interest-
ingly, although the DiI-labeled EPCs did appear to asso- these data suggest that OPN acts in an autocrine manner
on EPCs, resulting in the secretion of angiogenic proteins,ciate with the tubules formed in the angiogenesis assay
they did not appear to actually incorporate into the which then act to enhance both the ability of the EPCs to
adhere to sites of injury and to induce angiogenesis.tubule structures. Thus, we next questioned if the EPCs
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Exposure to OPN Enhances the Angiogenic Potential circulating EPCs was significantly reduced. Further-
more, we demonstrated that these EPCs were impairedof EPCs in OPN KO Mice
in both their ability to adhere to activated endothelialAlthough it appears that exposure to recombinant
cells and their ability to induce tubule formation, whichOPN induces the secretion of angiogenic proteins and
are two critical indicators of angiogenic potential in vivo.
enhances angiogenesis, it is unclear if this is sufficient
Having confirmed that EPC dysfunction exists in ato restore the angiogenic potential of EPCs in vivo.
homogenous cohort of T1DM patients, we used micro-Therefore, we induced hind limb ischemia in OPN KO
array analysis to identify gene expression differences,
mice and intramuscularly injected untreated KO EPCs,
which may explain this observation. OPN was one of aOPN-pretreated KO EPCs, or diluent alone (control).
number of genes found to be dysregulated in diabeticEPCs from OPN KO animals that were pretreated for 24
EPCs following microarray analysis and was confirmedh with recombinant OPN improved blood flow com-
to be downregulated by qRT-PCR. We proceeded topared to injection of cells that had not been precondi-
assess the vascular response to hind limb ischemia intioned or diluent alone (Fig. 7), suggesting that exposure
OPN KO mice. Our results were consistent with thoseto OPN is sufficient to increase the angiogenic potential
of Duval et al., who found OPN KO mice demonstrate
of OPN-deficient EPCs.
impaired angiogenesis in response to hind limb ischemia
(8). Interestingly, many studies have shown that OPN
DISCUSSION is upregulated in response to ischemia (4,18,20). These
studies suggest a critical role for OPN in the angiogenicRecent clinical trials, such as Transplantation of Pro-
genitor Cells and Regeneration Enhancement in Acute response but the mechanism is poorly understood. As
we demonstrated OPN expression is decreased in EPCsMyocardial Infarction (TOPCARE-AMI) and Therapeu-
tic angiogenesis by cell transplantation (TACT), have from diabetes mellitus, a condition with abnormal EPC
function, we hypothesized that the mechanism of OPN-suggested that autologous bone marrow-derived progen-
itor cell transplantation holds promise for the treatment mediated angiogenesis was via an interaction with EPCs.
We next studied the potential role of OPN in EPCof acute myocardial infarction (3,26) and peripheral vas-
cular disease (24). While these studies demonstrate the dysfunction using cells isolated from OPN KO mice.
OPN KO EPCs have a reduced ability to adhere to acti-safety of autologous cell transplantation and potential
for therapeutic benefit, the outcome may be compro- vated endothelial cells and to induce angiogenesis. Fur-
thermore, we found that conditioned media was able tomised by disease-induced cellular dysfunction. This
highlights the need to understand the mechanism of dys- induce angiogenesis in vitro, which suggests that EPCs
are secreting angiogenic factors, and this is supportedfunction associated with each disease state and how this
may limit the effectiveness of treatment. Understanding by recent studies where EPC-conditioned media was
demonstrated to contain angiogenic proteins and wasdisease-associated EPC dysfunction may allow reversal
prior to transplantation. In the current study we used able to induce an angiogenic response in vivo (6,15,17,
33). Interestingly, neutralization of OPN was not suffi-diabetes mellitus as a model of EPC dysfunction and
determined a mechanistic role for OPN. Furthermore, cient to dampen the angiogenic response induced by
CM. This implied that OPN was not directly responsiblewe showed that OPN plays a crucial role in EPC func-
tion in general and that the mechanism is via autocrine for the induction of angiogenesis as its presence was not
required in the assay itself. However, exposure of EPCssecretion of angiogenic factors from EPCs. We went on
to show that preincubation of dysfunctional EPCs (from to OPN during culture was critical to inducing angiogen-
esis, which suggested OPN may be acting in an auto-OPN KO mouse) with OPN enhanced the therapeutic
efficacy after cell transplantation. crine manner, stimulating EPCs to turn on a “master
switch”, thereby promoting angiogenesis via the secre-We used T1DM as a model of EPC dysfunction in
order to identify factors involved in cell dysfunction. tion of a variety of angiogenic proteins. Indeed, we
found that exposure to OPN was sufficient to restore theOthers have established that there are reduced numbers
of circulating EPCs in patients with both T1DM and secretion of at least three proangiogenic proteins to lev-
els observed in WT cells. All three angiogenic proteinsT2DM (23,31). However, patients with microvascular
complications were not excluded from these studies and identified, IL-6, FGF-α, and TGF-α, have been impli-
cated in wound healing and angiogenesis (22,28,34).it has been shown that EPC numbers are increased in
patients with diabetic retinopathy (2). Thus, we studied However, OPN has various cleavage and phosphoryla-
tion sites and additional studies need to be performeda population of T1DM patients without diabetic retinop-
athy or other confounding factors and found, in accor- to determine how OPN activates EPCs to release these
angiogenic factors.dance with the previous studies, that the number of
1106 VAUGHAN ET AL.
conditioned medium can replace progenitor cell transplan-While we and others have shown that a deficiency in
tation. PLoS One 4(5):e5643; 2009.OPN suppressed the angiogenic response in a murine 7. Duvall, C. L.; Taylor, W. R.; Weiss, D.; Wojtowicz, A. M.;hind limb ischemia model (8), this cannot be directly Guldberg, R. E. Impaired angiogenesis, early callus for-
attributed to OPN expression in EPCs. Using the OPN mation, and late stage remodeling in fracture healing of
osteopontin-deficient mice. J. Bone Miner. Res. 22(2):KO mouse as a model for EPC dysfunction, we exam-
286–297; 2007.ined the effectiveness of transplantation of OPN KO
8. Duvall, C. L.; Weiss, D.; Robinson, S. T.; Alameddine,EPCs preexposed to OPN in the response to hind limb
F. M.; Guldberg, R. E.; Taylor, W. R. The role of osteo-ischemia. Injection of OPN-treated EPCs significantly pontin in recovery from hind limb ischemia. Arterioscler.
enhanced and accelerated healing in the ischemic limbs, Thromb. Vasc. Biol. 28(2):290–295; 2008.
9. Fadini, G. P.; Miorin, M.; Facco, M.; Bonamico, S.;suggesting that preincubation of dysfunctional EPCs
Baesso, I.; Grego, F.; Menegolo, M.; de Kreutzenberg,with OPN may enhance their therapeutic efficacy.
S. V.; Tiengo, A.; Agostini, C.; Avogaro, A. CirculatingThis study shows for the first time that OPN plays a
endothelial progenitor cells are reduced in peripheral vas-
crucial role in EPC function and that this is at least in cular complications of type 2 diabetes mellitus. J. Am.
part due to an autocrine effect whereby OPN increases Coll. Cardiol. 45(9):1449–1457; 2005.
10. Furger, K. A.; Menon, R. K.; Tuck, A. B.; Bramwell, V.the secretion of angiogenic proteins from EPCs. This
H.; Chambers, A. F. The functional and clinical roles ofobservation followed on the recognition that OPN
osteopontin in cancer and metastasis. Curr. Mol. Med.expression in EPCs was reduced in diabetes mellitus, a 1(5):621–632; 2001.
model of EPC dysfunction and impaired angiogenesis 11. Haubner, R.; Weber, W. A.; Beer, A. J.; Vabuliene, E.;
and vascular healing. The data provide an important Reim, D.; Sarbia, M.; Becker, K. F.; Goebel, M.; Hein,
R.; Wester, H. J.; Kessler, H.; Schwaiger, M. Noninvasiveinsight into the mechanism of EPC-mediated angiogen-
visualization of the activated alphavbeta3 integrin in can-esis and also provide a target for reversal of EPC dys-
cer patients by positron emission tomography andfunction prior to autologous cell transplantation. In [18F]Galacto-RGD. PLoS Med. 2(3):e70; 2005.
addition, the data provide a rationale for attempted mod- 12. Hirama, M.; Takahashi, F.; Takahashi, K.; Akutagawa, S.;
ulation of OPN expression in EPCs as a therapy to Shimizu, K.; Soma, S.; Shimanuki, Y.; Nishio, K.;
Fukuchi, Y. Osteopontin overproduced by tumor cells actsrestore endogenous EPC function in vivo.
as a potent angiogenic factor contributing to tumor
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